AOAC 133rd Annual Meeting - Final Program

Poster Abstracts | Tuesday

P-T-037 Michele Yacopucci , Nancy Hall , Mark Pendergast , Dustin May , Brian Wels , Cathy Lord , Matthew Mainprize , Stephen Treimer , Susie Dai , University of Iowa, Coralville, IA, USA Medical Cannabis Testing Program and Method Validations in Iowa In May 2017, Iowa legalized medical cannabidiol and required testing of manufactured products for quality and safety. The State Hygienic Laboratory (SHL), Iowa’s public health laboratory, was required to test these products. Testing included potency, pesti- cides, residual solvent, metals and total yeast and mold count (TYMC), total aerobic microbial count (TAMC), Shiga-toxin producing E. coli , and Salmonella spp. SHL collaborated with stakeholders to establish a testing program that was fit-for-pur- pose and defensible while ensuring a quality product. Validation of the chemical methods in distillate was complicated by the unavailability of reference material. Method validations were performed by spiking analytes into similar blank matrices. Validation of active ingredients in final products was complicated due to the concentration limit of commercially available pure standards (<1 mg/ml). For the TAMC and TYMC validations, the USP 61 Microbiological Examination of Nonsterile Products protocol using the three recommended organisms was followed. For the pathogen analysis, the FSIS FERN validation guidelines were followed. Two levels of spiking concentrations were used. Performance characteristics for the single-laboratory validations were determined as appropriate for each test (selectivity; LOD & LOQ; working and linear ranges; bias and recovery; intermedi- ate precision; measurement uncertainty; and robustness). Presenter: Michele Yacopucci, University of Iowa, Coralville, IA, USA, Email: michele-yacopucci@uiowa.edu P-T-038 Maria Ofitserova , Sareeta Nerkar , Pickering Laboratories, Inc., Mountain View, CA, USA Analysis of Mycotoxins in Cannabis Plant and Cannabis-Containing Products As medical and recreational Cannabis use gains broader accep- tance, regulations are being put in place to mandate the testing of consumer products containing Cannabis. Legally available Cannabis plant and cannabis-containing edible products are tested for presence of pesticides, heavy metals, residual solvents and other harmful substances. State regulations have established maximum allowed levels for total Aflatoxins and Ochratoxin A in cannabis products, and laboratories are looking for methods to analyze these compounds. We present easy and sensitive method to analyze Aflatoxins B1, B2, G1, G2, and Ochratoxin A in cannabis plant and edible products. Mycotoxins are isolated using immunoaffinity clean-up columns and analyzed with fluorescence detection. To increase sensitivity of Aflatoxins B1 and G1, an in-line photochemical reactor is installed before the detector. This method utilizes standard HPLC equipment and allows laboratories to easily determine Mycotoxins at levels below the limits established by state regulations. Presenter: Maria Ofitserova, Pickering Laboratories, Inc., Mountain View, CA, USA, Email: maria_o@pickeringlabs.com

market has outpaced the development of robust analytical test procedures to accurately demonstrate quality, purity, potency and authenticity of medical cannabis and CBD products. In this work, we present the development of a quantitative NMR method for testing finished products containing CBD. Sample preparation is relatively fast and easy, and 1 H NMR data collection takes mere minutes. From the resulting NMR data, we are able to accurately quantify CBD, cannabi- diolic acid (CBDA), Δ 9 -tetrahydrocannabinol (THC) and Δ 9 -tetrahydrocannabinolic acid (THCA). Quantitation of CBD and total THC content (THC + THCA) is important for establish- ing veracity of label claims of CBD and THC content. Further, the 1 H NMR spectrum represents the distinct chemical finger- print of each product, which may be used for provenience testing and authenticity control when combined with multivar- iate statistical methods. Thus, NMR spectroscopy provides a vast amount of useful information that can be used to establish quality, purity, potency and provenience of medical cannabis and CBD products. Presenter: Kristie Adams, Steelyard Analytics, Inc., Gaithersburg, MD, USA, Email: kristie.adams@steelyardanalytics.com P-T-036 Thu Huynh , Kirsten Mercado , Byungchul Kim , Wondu Wolde-Mariam , Hygiena, Santa Ana, CA, USA Development of an Enzyme-Linked Immunoassay for Determination of D9-tetrahydrocannabinol in Cannabis and Hemp Products The growing cannabis industry has resulted in a proliferation of state regulations to ensure the quality and safety of canna- bis products. Cannabis suppliers must label the level of total tetrahydrocannabinol (THC) and cannabidiol (CBD) in their products. Additionally, hemp suppliers in the United States must show their products contain <0.3% THC. Several methods for potency measurement have been developed, including high-per- formance liquid chromatography (HPLC). However, there are drawbacks. For instance, HPLC is time intensive, requires sample clean-up, advanced training, and can be costly. We developed an enzyme-linked immunoassay (ELISA) capable of detect- ing the psychoactive compound, D9-tetrahydrocannabinol (D9-THC) from cannabis and hemp products. The D9-THC ELISA measures %THC in a variety of products by altering the dilution to accurately measure the broad range of THC levels among disparate sample types. Validation studies were performed on market products and spiked materials, and the %THC recovered was 85-113%. A D9-THC proficiency sample was measured to contain 390.218 mg/mL, which was within the acceptable range of 291-540 mg/mL. A hemp oil proficiency sample was also tested and shown to contain 0.6989 mg/mL, which was within the acceptable range of 0.612-1.14 mg/mL. This assay may be useful to the cannabis and hemp value chain from growers to manufacturers of edibles who need rapid, cost-effective screen- ing methods for measuring D9-THC concentration. Presenter: Byungchul Kim, Hygiena, Santa Ana, CA, USA, Email: bkim@hygiena.com

68 SEPTEMBER 6–12, 2019 SHERATON DENVER DOWNTOWN HOTEL